Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
Suhara Y, Urabe F, Yoshihara K, Kurawaki S, Fukuokaya W, Iwatani K, Imai Y, Sakanaka K, Hisakane A, Kurauchi T, Kayano S, Onuma H, Mori K, Kimura S, Tashiro K, Tsuzuki S, Miki J, Sato S, Takahashi H, Kimura T; JIKEI YAYOI Collaborative Group. Suhara Y, et al. Among authors: sakanaka k. Int J Urol. 2024 Feb;31(2):125-132. doi: 10.1111/iju.15321. Epub 2023 Oct 12. Int J Urol. 2024. PMID: 37828777
Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K, Kimura T, Fukuokaya W, Iwatani K, Sakanaka K, Kurokawa G, Yanagisawa T, Sasaki H, Miki J, Shimomura T, Miki K, Hatano T, Endo K, Egawa S. Mori K, et al. Among authors: sakanaka k. Int J Clin Oncol. 2020 Mar;25(3):479-485. doi: 10.1007/s10147-019-01541-8. Epub 2019 Sep 11. Int J Clin Oncol. 2020. PMID: 31512007
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T, Iwamoto Y, Fukuokaya W, Miyajima K, Enei Y, Sakanaka K, Matsukawa A, Onuma H, Obayashi K, Tsuzuki S, Hata K, Shimomura T, Miki J, Egawa S. Yanagisawa T, et al. Among authors: sakanaka k. Prostate. 2022 Jan;82(1):3-12. doi: 10.1002/pros.24243. Epub 2021 Sep 24. Prostate. 2022. PMID: 34559410
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S. Yanagisawa T, et al. Among authors: sakanaka k. World J Urol. 2023 Aug;41(8):2051-2062. doi: 10.1007/s00345-022-04030-2. Epub 2022 May 21. World J Urol. 2023. PMID: 35596809 Free PMC article.
En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
Yanagisawa T, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Yorozu T, Fukuokaya W, Sakanaka K, Urabe F, Kimura S, Tsuzuki S, Shimoda M, Takahashi H, Miki J, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: sakanaka k. Ann Surg Oncol. 2023 Jun;30(6):3820-3828. doi: 10.1245/s10434-023-13227-7. Epub 2023 Mar 10. Ann Surg Oncol. 2023. PMID: 36897417
[No title available]
[No authors listed] [No authors listed] PMID: 37040049
81 results